Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01661595 · ClinicalTrials.gov registry record · NA

The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue

A NA study, sponsored by The University of Texas Medical Branch, Galveston.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT01661595: Completed NA study, sponsored by The University of Texas Medical Branch, Galveston.

NCT01661595 is a NA study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01661595, a NA study, has completed, sponsored by The University of Texas Medical Branch, Galveston.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

This study is funded by the Moody Endowment. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on skeletal muscle anabolism, muscle strength, physical function, and body composition in older individuals. Further, we will determine whether augmentation of NO-mediated signaling reduces fatigue and fatigability.

Primary Outcome

Isokinetic Fatigue Measure (knee extension) is measured on a Biodex System Pro 4 within a 75 degree range of motion. Subjects performed concentric contractions at a fixed speed of 120 degree/sec. 50 contractions were performed at 100% force, one contraction every second. Isokinetic fatigue will be measured at week 4 and week 8. Depending on grouping, the week 4 and week 8 measures may be placebo or active drug. Data will be reported as after 4 weeks of placebo or after 4 weeks of active drug. Da

Interventions

  • DRUG Placebo
  • DRUG Sildenafil
  • DRUG tadalafil

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2012-11
Est. Completion 2015-06
Phase NA

What the finished NCT01661595 record still lists

NCT01661595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01661595 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01661595 about?

NCT01661595 is a clinical study titled "The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue". This study is funded by the Moody Endowment. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on skeletal muscle anabolism, muscle strength, physical function, and body composition in older individuals. Further, we will determine whether augme...

What is the current status of trial NCT01661595?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2012-11. Estimated completion is 2015-06.

What interventions are being tested in trial NCT01661595?

The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG), tadalafil (DRUG).

Who is sponsoring clinical trial NCT01661595?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01661595's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01661595, the US trial registry maintained by the National Library of Medicine. NCT01661595 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.